BioCentury | Jul 2, 2018
Company News

Dunsire to become Lundbeck CEO

...since November; he will remain CFO after Dunsire's arrival. Dunsire was president and CEO of XTuit Pharmaceuticals Inc....
...BioCentury that XTuit has shut down (see "XTuit Taps Dunsire as CEO" ). Prior to XTuit...
...Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Mary Romeo Forum Pharmaceuticals Inc. H. Lundbeck A/S Takeda Pharmaceutical Co. Ltd. Teva Pharmaceutical Industries Ltd. Xtuit Pharmaceuticals Inc....
BioCentury | Nov 14, 2017
Regulation

Rules of engagement

...its treatments, and their preferences in clinical trial design. Deborah Dunsire, president and CEO of Xtuit Pharmaceuticals Inc....
...line is pretty obvious, and a reasonable person could make that call.” Michael Kauffman, Karyopharm Xtuit...
...developing treatments for cancer and fibrotic disease. Dunsire said before beginning clinical studies next year, Xtuit...
BioCentury | Mar 8, 2017
Company News

XTuit taps Dunsire as CEO

...president and CEO of the Millennium Pharmaceuticals Inc. subsidiary of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). XTuit...
...BioCentury the company expects its first candidate to enter the clinic in 2018. In 2015, XTuit...
...raised $22 million in a series A round (see BioCentury Extra, June 11, 2015) . Becky Simon Xtuit Pharmaceuticals Inc....
BioCentury | Jun 15, 2015
Financial News

Xtuit completes venture financing

Xtuit Pharmaceuticals Inc. , Cambridge, Mass. Business: Cancer, Hepatic Date completed: 2015-06-11 Type: Venture financing Raised: $22 million Investors: New Enterprise Associates; Polaris Partners; CTI Life Sciences Fund; Arcus Ventures; Omega Funds WIR Staff cancer Hepatic...
BioCentury | Jun 12, 2015
Financial News

XTuit raises $22 million in series A

...Life Sciences, Arcus Ventures and Omega Funds also participated, as did founding investor Polaris Partners. XTuit...
...XTuit declined to disclose its timeline for starting clinical studies. NEA's David Mott will join XTuit's...
Items per page:
1 - 5 of 5
BioCentury | Jul 2, 2018
Company News

Dunsire to become Lundbeck CEO

...since November; he will remain CFO after Dunsire's arrival. Dunsire was president and CEO of XTuit Pharmaceuticals Inc....
...BioCentury that XTuit has shut down (see "XTuit Taps Dunsire as CEO" ). Prior to XTuit...
...Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Mary Romeo Forum Pharmaceuticals Inc. H. Lundbeck A/S Takeda Pharmaceutical Co. Ltd. Teva Pharmaceutical Industries Ltd. Xtuit Pharmaceuticals Inc....
BioCentury | Nov 14, 2017
Regulation

Rules of engagement

...its treatments, and their preferences in clinical trial design. Deborah Dunsire, president and CEO of Xtuit Pharmaceuticals Inc....
...line is pretty obvious, and a reasonable person could make that call.” Michael Kauffman, Karyopharm Xtuit...
...developing treatments for cancer and fibrotic disease. Dunsire said before beginning clinical studies next year, Xtuit...
BioCentury | Mar 8, 2017
Company News

XTuit taps Dunsire as CEO

...president and CEO of the Millennium Pharmaceuticals Inc. subsidiary of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). XTuit...
...BioCentury the company expects its first candidate to enter the clinic in 2018. In 2015, XTuit...
...raised $22 million in a series A round (see BioCentury Extra, June 11, 2015) . Becky Simon Xtuit Pharmaceuticals Inc....
BioCentury | Jun 15, 2015
Financial News

Xtuit completes venture financing

Xtuit Pharmaceuticals Inc. , Cambridge, Mass. Business: Cancer, Hepatic Date completed: 2015-06-11 Type: Venture financing Raised: $22 million Investors: New Enterprise Associates; Polaris Partners; CTI Life Sciences Fund; Arcus Ventures; Omega Funds WIR Staff cancer Hepatic...
BioCentury | Jun 12, 2015
Financial News

XTuit raises $22 million in series A

...Life Sciences, Arcus Ventures and Omega Funds also participated, as did founding investor Polaris Partners. XTuit...
...XTuit declined to disclose its timeline for starting clinical studies. NEA's David Mott will join XTuit's...
Items per page:
1 - 5 of 5